Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-06-05

Last Posted Date: 2013-02-04

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Registration Number: NCT00008203

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2003-06-02

Last Posted Date: 2013-06-24

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT00006484

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

and more 90 locations

Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

First Posted Date: 2003-05-30

Last Posted Date: 2013-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00006377

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

BMS-188797 and Carboplatin in Treating Patients With Advanced Nonhematologic Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-05-22

Last Posted Date: 2010-09-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT00006086

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Phase 2

Completed

Conditions: Brain Tumors
Central Nervous System Tumors
Neuroblastoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: vincristine sulfate
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2003-05-19

Last Posted Date: 2013-08-23

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 168

Registration Number: NCT00003203

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇨🇦
British Columbia Children's Hospital, Vancouver, British Columbia, Canada

and more 35 locations

Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-05-16

Last Posted Date: 2015-06-08

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 44

Registration Number: NCT00005078

Locations: 🇺🇸
City of Hope Medical Group, Pasadena, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States

and more 1 locations

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx

Phase 2

Conditions: Head and Neck Cancer

First Posted Date: 2003-05-08

Last Posted Date: 2014-01-06

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004094

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Monroe Medical Associates, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 1 locations

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Phase 2

Completed

Conditions: Breast Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Testicular Germ Cell Tumor
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-05-07

Last Posted Date: 2013-05-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 451

Registration Number: NCT00060255

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIA Non-small Cell Lung Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: motexafin gadolinium
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00005065

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Ovarian Serous Cystadenocarcinoma
Primary Peritoneal Carcinoma
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Brenner Tumor
Fallopian Tube Carcinoma
Malignant Ovarian Mixed Epithelial Tumor
Ovarian Mucinous Cystadenocarcinoma
Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel Poliglumex
Other: Pharmacological Study

First Posted Date: 2003-05-07

Last Posted Date: 2015-05-08

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 32

Registration Number: NCT00060359

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy